BRIEF-Incyte says Baricitinib significantly reduces joint damage progression in rheumatoid arthritis

Thu Jun 9, 2016 7:05am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

June 9 (Reuters) - Incyte Corp

* Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional dmards

* Findings demonstrate baricitinib superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis Source text for Eikon: Further company coverage: )